Growth suppression of human lung cancer cells and implanted tumors by adenovirus-mediated transfer of the PTEN gene

Abstract

This study examined the effects of a recombinant adenovirus Ad-PTEN-EGFP on the proliferation of A549 cells, a human lung carcinoma cell line, in vitro and on the growth of the implanted tumors in the nude mice in vivo, explored the underlying mechanisms and evaluated the in vitro transfection efficiency of Ad-PTEN-EGFP into A549 cells. The expression of Ad-PTEN-EGFP in the A549 cells was determined. The proliferation and the apoptosis rates of the A549 cells with Ad-PTEN-EGFP transfection or not was detected by MTT and flow cytometry. Ad-PTEN-EGFP at different doses was injected intratumorally to the tumor-bearing mice induced by the A549 cells. Tumor sizes were measured on an alternate day. After all the mice were sacrificed, the implanted tumors were removed for routine histological examination, weight test, HE staining and immunohistochemical staining. The expressions of Bax, P16 and P53 in the tumor tissues and those of caspase-3, CD34 and VEGF in the mouse sera were detected. Tumor cell apoptosis was measured by TUNEL method. The results showed that the vitality of the A549 cells after transfection with Ad-PTEN-EGFP declined. The expression of green fluorescent protein was observed under fluorescent microscope. The transfection rate was in excess of 50%. The mRNA and protein expression of PTEN in the transfected cells was confirmed. The proliferation rate of the transfected cells was significantly decreased when compared with that of the non-transfected cells (P<0.05). The number of the apoptosis cells was increased in the transfected cells (P<0.05). The models of implanted tumors were successfully established by injection of the A549 cells in the flank of Balb/c nude mice. Administration of Ad-PTEN-EGFP to the tumor-bearing nude mice resulted in a suppression of tumor growth. There were statistically significant differences in the tumor weight and tumor volume between the Ad-PTEN-EGFP-treated group and the control groups (P<0.05). In contrast to those in the control groups, tumor tissues in the Ad-PTEN-EGFP-treated group were shown to have typical extensive vacuolar degeneration and massive hemorrhagic necrosis. Apoptotic bodies were also observed in the tumor cells. The expressions of Bax, caspase-3 and P16 were increased (P<0.05) while those of CD34, VEGF and P53 decreased (P<0.05) in the Ad-PTEN-EGFP-treated group. It is concluded that Ad-PTEN-EGFP could induce the apoptosis of the A549 cells and inhibit their proliferation. And it could also substantially suppress the tumor growth in the tumor-bearing nude mice and induce apoptosis of the tumor cells as well. These findings carry significant implications for adenovirus vector-based PTEN gene therapies for lung cancers.

Keywords

lung carcinoma / PTEN / adenovirus

References

[1] LiJ., YenC., LiawD., et al.. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997, 275(20): 1943-1947

[2] WangY.E., WuX., SuzukiH., et al.. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA, 1998, 95(6): 5246-5252

[3] TengD.H., HuR., LinH., et al.. MMAC1/PTEN mutation in primary tumor specimens and tumor cell lines. Cancer Res, 1997, 57(8): 5221-5229

[4] JingR.R., WangH.M., JuS.Q., et al.. Establishment of a real-time quantitative polymerase chain reaction for detection of human receptor for advanced glycation end products (RAGE) mRNA and its preliminary application. Chin J Clin Lab Sci, 2008, 6(1): 55-58

[5] LiT., MaC.S., LiC., et al.. Western blot assay of MAGE-1 protein in non-small cell lung cancer. Prac J Med & Pharm, 2008, 12(2): 219-221

[6] WeiW.Q., ZhaoM.C., LiuJ., et al.. Methodological studies on the anti-cancer drug sensitivity of cancer cells with MTT colormetric assay. Chin Clin Oncol (Chinese), 2008, 10(2): 871-874

[7] JiaoZ.J., YouH.Y., ChenL., et al.. Detection of FoxP3-expressing CD4⁺CD25⁺ regulatory T cells by flow cytometry. Chin Clin Lab Sci (Chinese), 2008, 6(3): 161-163

[8] WengH.B., LiS., RenJs.. Significance and expression of PTEN in breast cancer. J Clin Exp Med, 2008, 12(1): 6-7

[9] SaitoY., SwansonX., MhashilkarA.M., et al.. Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther, 2003, 10(23): 1961-1969

[10] SunH., LescheR., LiD.M., et al.. PTEN modulates cell cycle progression and cell survival by regulating phophatidylinosioal 3,4,5,-trisphophate and Akt/prote in kinase B signaling pathway. Proc Natl Acad Sci USA, 1999, 96(11): 6199-6204

[11] CheneyI.W., JohnsonD.E., VaillancourtM.T., et al.. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res, 1998, 58(11): 2331-2334

[12] TanakaM., GrossmanH.B.. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther, 2003, 10(19): 1636-1642

[13] SeminarioM.C., PrechtP., WerstoR.P., et al.. PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression. Oncogene, 2003, 22(50): 8195-8204

[14] KuroseK., ZhouX.P., ArakiT.. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclinD 1 expression, in primary epithelial ovarian carcinomas. Am J Pathol, 2001, 158(6): 2097-2106

[15] RamaswamyS., NakamuraN., VazquezF., et al.. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA, 1999, 96(5): 2110-2115

[16] YuanX.J., WhangY.E.. PTEN sensitizes prostate cancer cells to death receptor mediated and drug induced apoptosis through a FADD-dependent pathway. Oncogene, 2002, 21(2): 319-327

[17] SchwartzbauerG., RobbinsJ.. The tumor suppressor gene pten can regulate cardiac hypertrophy and survival. J Biol Chem, 2001, 276(38): 35786-35793

[18] HwangP.H., YiH.K., KimD.S., et al.. Suppression of tumorigenicity and metastasis in B16F10 Cells by PTEN/MMAC1/TEP1 gene. CancerLett, 2001, 172(1): 83-91

[19] ChenJ., DeS., BrainardJ., et al.. Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun Adhes, 2004, 11(1): 1-11

[20] ZhangT.Y., AnJ.L., GuJ.Y., et al.. Expression of PTEN, Cx43, and VEGF in hepatocellular carcinoma. Ai Zheng (Chinese), 2004, 23(6): 662-666

[21] IdoateM.A., SoriaE., LozanoM.D., et al.. PTEN protein expression correlates with PTEN gene molecular changes but not with VEGF expression in astrocytomas. Diagn Mol Pathol, 2003, 12(3): 160-165

[22] ChungM.J., JungS.H., LeeB.J., et al.. Inactivation of the PTEN gene protein products associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int, 2004, 54(1): 10-15